Lichen planus-like drug eruptions due to β-blockers: A case report and literature review

American Journal of Clinical Dermatology

Volumn 13, Issue 6, 2012, Pages 417-421

  Fessa, Chris ^a   Lim, Penny ^b   Kossard, Steve ^b   Richards, Shawn ^b   Peñas, Pablo Fernandez ^a,b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b SKIN AND CANCER FOUNDATION AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Beta adrenergic receptor antagonists; Cross reactivity; Labetalol; Lichen planus; Lichenoid eruptions

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LABETALOL; LEVOBUNOLOL; METOPROLOL; NEBIVOLOL; OXPRENOLOL; PINDOLOL; PROPRANOLOL; SOTALOL; TIMOLOL;

ADRENERGIC SYSTEM; ADULT; ALOPECIA; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DRUG CROSS REACTIVITY; DRUG ERUPTION; DRUG WITHDRAWAL; ECZEMA; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; HYPERTENSION; LICHEN PLANUS; LICHEN PLANUS LIKE DRUG ERUPTION; LICHEN PLANUS LIKE DRUG REACTION; LICHENOID ERUPTION; LUPUS ERYTHEMATOSUS; MALE; PEYRONIE DISEASE; PRIORITY JOURNAL; PSORIASIFORM ERUPTION; RASH; RAYNAUD PHENOMENON; REVIEW; SCALP PRURITUS; TOXIC EPIDERMAL NECROLYSIS; XEROSIS;

ADRENERGIC BETA-ANTAGONISTS; DRUG ERUPTIONS; HUMANS; LABETALOL; LICHEN PLANUS; MALE; MIDDLE AGED;

EID: 84867429141     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11634590-000000000-00000     Document Type: Review

References (40)

1. Richards S. Cutaneous side-effects of beta-adrenergic blockers. Aust J Derm 1985; 26: 25-8
2. Belrani VS. Cutaneous manifestations of adverse drug reactions. Immunol Allergy Clin North Am 1998; 18: 867-95
3. Upadhayai JB, Nangia AK, Mukhija RD, et al. Cutaneous reactions due to antihypertensive drugs. Indian J Dermatol 2006; 51: 189-91
4. Abraham J, Davis C. Testing times: The emergence of the practolol disaster and its challenge to British drug regulation in the modern period. Soc Hist Med 2006; 19: 127-47
5. Kaomongkolgit R. Oral lichenoid drug reaction associated with antihypertensive and hypoglycaemic drugs. J Drugs Dermatol 2010; 9: 73-5
6. Oliver FG, Winkelmann RK, Muller SA. Lichenoid dermatitis: A clinicopathologic and immunopathologic review of sixty-two cases. J Am Acad Dermatol 1989; 21: 284-92
7. Van der Haute V, Lachapelle AJM. Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: Retrospective study on selected samples. Dermatologica 1989; 179: 10-3
8. Hawk JLM. Lichenoid drug eruption induced by propanolol. Clin Exp Dermatol 1980; 5: 93-6
9. Massa MC, Jason SM, Gradini R, et al. Lichenoid drug eruption secondary to propranolol. Cutis 1991; 48: 41-3
10. Finlay AY, Waddington E, Savage RL. Cutaneous reactions to labetalol. BMJ 1987; 1 (6118): 987
11. Gange RW, Jones EW. Bullous lichen planus caused by labetalol. BMJ 1978; 1 (6116): 816-7
12. Staughton R, Sutton R, Farrell M. b-Blockers, autoimmunity and rashes. Lancet 1980; 2 (8194): 581
13. Beckman KA, Chanes L, Kaufman SR. Lichen planus associated with topical beta-blocker therapy. Am J Ophthalmol 1995; 4: 530-1
14. Meyer S, Burgdorff SM, Szeimies TV, et al. Management of erosive lichen planus with topical tacrolimus and recurrence secondary to metoprolol. JEADV 2005; 19: 236-9
15. O'Brien TJ, Lyall IG, Reid SS. Lichenoid eruption induced by sotalol. Australas J Dermatol 1994; 35: 93-4
16. Taylor AE, Hindson C, Wacks H. A drug eruption due to acebutolol with combined lichenoid and lupus erythematous features. Clin Exp Dermatol 1982; 7: 219-21
17. Mullins RJ, Lones R, Dutta B. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops. Australas J Dermatol 2004; 45: 151-2
18. Bodmer M, Egger SS, Hohenstein E, et al. Lichenoid eruption associated with the use of nebivolol. Ann Pharmacother 2006; 40 (9): 1688-90
19. Wiesenfeld D, Scully C, MacFadyen EE. Multiple lichenoid drug reactions in a patient with Ferguson-Smith disease. Oral Surg Oral Med Oral Pathol 1982; 54: 527-9
20. RuizVR, BlascoMJ,MendozaGF, et al.Generalized lichen planus-like eruption due to acetylsalicylic acid. J Eur Acad Dermatol Venereol 2003; 17: 470-2
21. Firth NA, Reade PC. Angiotensin-converting enzyme inhibitors implicated in oralmucosal lichenoid reactions. Oral Surg OralMedOral Pathol 1989; 67: 41-4
22. Lakshmi C, Srinivas CR, Ramachandran B, et al. Perforating lichenoid reaction to amlodipine. Indian J Dermatol 2008; 53 (2): 98-9
23. Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol 1993; 29: 249-55
24. Clayton R, Chaudhry S, Ali I, et al. Mucosal (oral and vulval) lichen planus in women: Are angiotensin-converting enzyme inhibitors protective, and betablockers and non-steroidal anti-inflammatory drugs associated with the condition? Clin Exp Dermatol 2009; 35: 384-7
25. Habbab KM, Moles DR, Porter SR. Potential oral manifestations of cardiovascular drugs. Oral Dis 2010; 16: 769-73
26. Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol 1998; 19: 325-32
27. Ramdial PK, Naidoo DK. Drug-induced cutaneous pathology. J Clin Pathol 2009; 62: 493-504
28. Justiniano H, Berlingeri-Ramos AC, Sanchez JL. Pattern analysis of drugiduced skin diseases. Am J Dermatopathol 2008; 30: 352-69
29. Crowson NA, Magro C, Mihm M. Interface dermatitis. Arch Pathol Lab Med 2008; 132: 652-65
30. West AJ, Berger TG, LeBoit PE. A comparative histopathologic study of photodistributed and nonphotodistributed lichenoid drug eruptions. J Am Acad Dermatol 1990; 23: 689-93
31. Lodi G, Scully C, Carrozzo M. Current controversies in oral lichen planus: Report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Radiol Endod 2005; 100: 40-51
32. Shiohara T, MizukawaY. The immunological tissue reaction. Autoimmun Rev 2005; 4: 236-41
33. Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: Clinical and histological perspectives. J Invest Dermatol 2009; 129: 1088-99
34. Chen J, Hoffman BB, Isseroff RR. Adrenergic receptor activation inhibits keratinocyte migration via a cyclic adenosine monophosphate-independent mechanism. J Invest Dermatol 2002; 119: 1261-8
35. Manni M, Maestroni GJ. Sympathetic nervous modulation of the skin innate and adaptive immune response to peptidoglycan but not lipopolysaccharide: Involvement of beta-adrenoceptors and relevance in inflammatory diseases. Brain Behav Immun 2008; 22 (1): 80-8
36. Sivamani RK, Lam ST, Isseroff RR. Beta adrenergic receptors in keratinocytes. Dermatol Clin 2007; 25 (4): 643-53
37. Steinkraus V, Steinfath M, Stö ve L. Beta-adrenergic receptors in psoriasis: Evidence for down-regulation in lesional skin.ArchDermatol Res 1993; 285: 300-4
38. Schallreuter KU, Wood JM, Pittelkow MR, et al. Increased in vitro expression of beta 2-adrenoceptors in differentiating lesional keratinocytes of vitiligo patients. Arch Dermatol Res 1993; 285 (4): 216-20
39. Gold MH, Holy AK, Roenigk HH. Beta-blocking drugs and psoriasis: A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol 1988; 19 (5): 837-41
40. Steinkraus V, Mak JC, Pichmeirer U. Autoradiographic mapping of betaadrenoceptors in human skin. Arch Dermatol Res 1996; 288: 549-53